ArticleSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association2026
Trends in the burden and quality of care for upper gastrointestinal diseases from 1990 to 2021: An analysis of the global burden of disease study 2021.
Article in Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on global trends in the burden and quality of care for upper gastrointestinal diseases, 1990-2021.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Upper gastrointestinal (GI) diseases, primarily gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and gastritis and duodenitis (GD), are highly prevalent, chronic, and recurrent conditions worldwide, imposing a substantial burden on population health and quality of life. However, long-term trends in their quality of care and the disease-specific burden remain poorly characterized. This study aimed to analyze global trends in the disease burden and quality of care for upper-GI diseases, from 1990 to 2021. Methods: Based on data from the Global Burden of Disease Study 2021, we analyzed the global temporal trends in the incidence, prevalence, mortality, disability-adjusted life-years (DALYs), years of life lost, years lived with disability, and their age-standardized rates of upper-GI diseases and the three main subtypes (GERD, PUD and GD), from 1990 to 2021. We further assessed trends in the Quality-of-Care Index (QCI) and examined variations across regions, sexes, and age groups. Additionally, we conducted cross-national inequality analyses. Results: From 1990 to 2021, global case numbers of upper-GI diseases increased by 77.185% for incidence and 81.033% for prevalence, with modest rises in age-standardized incidence rate (ASIR; +1.794%) and prevalence rate (+2.130%). Age-standardized mortality rate and DALYs rate (ASDR) declined by 59.778% and 43.041%, respectively. The global QCI continued to rise, reaching 92.403 in 2021 with an estimated annual percentage change (EAPC) of 0.269 (95% CI: 0.262–0.276). Regions with lower sociodemographic indices (SDI) showed poorer care quality but greater improvement (EAPC =0.561). Females consistently maintained higher QCI scores than males, though this sex gap gradually narrowed. QCI declined with advancing age in elderly populations. Cross-national inequality analysis revealed that in 2021, the global slope index of inequality and concentration index for QCI were 9.612 (95% CI: 7.515–11.708) and 0.010 (95% CI: 0.005–0.014), respectively, showing reductions compared to 1990. Analysis of the component diseases revealed marked heterogeneity: the ASIR and ASDR for GERD showed an upward trend, whereas the corresponding indicators for PUD and GD declined substantially. Conclusion: During 1990–2021, despite the global trends of improvements in disease burden and the quality of care for upper-GI diseases, heterogeneity among diseases and inequalities in healthcare quality remain. Future efforts should prioritize international collaboration, particularly through targeted health system support for low-SDI countries, and adopt disease-specific, differentiated interventions aligned with each condition’s epidemiological profile, to advance global health equity goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.